JP2019507759A - 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット - Google Patents

外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット Download PDF

Info

Publication number
JP2019507759A
JP2019507759A JP2018544888A JP2018544888A JP2019507759A JP 2019507759 A JP2019507759 A JP 2019507759A JP 2018544888 A JP2018544888 A JP 2018544888A JP 2018544888 A JP2018544888 A JP 2018544888A JP 2019507759 A JP2019507759 A JP 2019507759A
Authority
JP
Japan
Prior art keywords
als3
polypeptide
subject
micrograms
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018544888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507759A5 (cg-RX-API-DMAC7.html
Inventor
ジョン イー. ジュニア エドワーズ,
ジョン イー. ジュニア エドワーズ,
スコット ジー. フィラー,
スコット ジー. フィラー,
ジョン ピー. ジュニア ヘネシー,
ジョン ピー. ジュニア ヘネシー,
マイケル ティモシー クック,
マイケル ティモシー クック,
ジャック ディー. ソーベル,
ジャック ディー. ソーベル,
Original Assignee
ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
ノバダイム セラピューティクス, インコーポレイテッド
ノバダイム セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター, ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター, ノバダイム セラピューティクス, インコーポレイテッド, ノバダイム セラピューティクス, インコーポレイテッド filed Critical ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
Publication of JP2019507759A publication Critical patent/JP2019507759A/ja
Publication of JP2019507759A5 publication Critical patent/JP2019507759A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2018544888A 2016-03-09 2017-03-07 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット Pending JP2019507759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305714P 2016-03-09 2016-03-09
US62/305,714 2016-03-09
PCT/US2017/021094 WO2017155949A1 (en) 2016-03-09 2017-03-07 Methods and kits for use in preventing and treating vulvovaginal candidiasis

Publications (2)

Publication Number Publication Date
JP2019507759A true JP2019507759A (ja) 2019-03-22
JP2019507759A5 JP2019507759A5 (cg-RX-API-DMAC7.html) 2020-04-16

Family

ID=59790870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544888A Pending JP2019507759A (ja) 2016-03-09 2017-03-07 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Country Status (5)

Country Link
US (1) US10857216B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426287A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019507759A (cg-RX-API-DMAC7.html)
CN (1) CN108883167A (cg-RX-API-DMAC7.html)
WO (1) WO2017155949A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー- ユーシーエルエー メディカル センター Candida auris感染症の治療方法
EP3552620A1 (en) * 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods of treatment for candida auris infections
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole
JP2022191716A (ja) 2021-06-16 2022-12-28 ローム・アンド・ハース・エレクトロニック・マテリアルズ・コリア・リミテッド Uv硬化性シリコーン組成物及びその硬化物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005323598A (ja) * 1996-09-04 2005-11-24 Takara Bio Inc 真菌抗原及びその製造方法
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
JP2014521605A (ja) * 2011-07-22 2014-08-28 ノバダイム セラピューティクス, インコーポレイテッド Staphylococcusaureusに対してワクチン接種するための方法および組成物
WO2014144211A2 (en) * 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
JP3717104B2 (ja) 2000-05-30 2005-11-16 シャープ株式会社 回路内蔵受光素子
FR2814741B1 (fr) 2000-09-29 2004-02-27 Atofina Procede de stabilisation de monomeres acryliques
US6579820B2 (en) 2001-03-21 2003-06-17 The Boc Group, Inc. Reactor modifications for NOx reduction from a fluid catalytic cracking regeneration vessel
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
DE10216281B4 (de) 2002-04-12 2007-04-12 Noé, Reinhold, Prof. Dr.-Ing. Anordnung und Verfahren für eine Dispersionsdetektion
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
US6935255B2 (en) 2003-08-08 2005-08-30 Deere & Company Auxiliary seed hopper having a removable screen
BRPI0416205A (pt) 2003-11-21 2006-12-26 Pfizer Prod Inc uso de antibióticos como adjuvantes de vacina
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
US7971912B2 (en) 2005-04-07 2011-07-05 Sanoh Kogyo Kabushiki Kaisha Quick connector
US7320467B2 (en) 2005-06-03 2008-01-22 Mattel, Inc. Narrating games
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
WO2007123850A2 (en) 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2296698A1 (en) 2008-05-29 2011-03-23 Intervet International BV Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
ES2606555T3 (es) 2009-07-03 2017-03-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 como objetivo para la inmunización activa y pasiva contra Candida
US9462734B2 (en) 2010-04-27 2016-10-04 Alion Energy, Inc. Rail systems and methods for installation and operation of photovoltaic arrays
EP2403118A3 (en) 2010-07-01 2014-10-29 Kabushiki Kaisha Yaskawa Denki Actuator
KR101075495B1 (ko) 2010-07-06 2011-10-21 주식회사 하이닉스반도체 반도체 모듈에 포함된 다수의 반도체 장치를 선택하는 회로 및 그 동작방법
US20120023753A1 (en) 2010-08-02 2012-02-02 Hao Wen knife having a locking mechanism
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
AU2012308281A1 (en) 2011-09-14 2014-04-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1-derived compositions and methods of treatment using same
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005323598A (ja) * 1996-09-04 2005-11-24 Takara Bio Inc 真菌抗原及びその製造方法
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
JP2014521605A (ja) * 2011-07-22 2014-08-28 ノバダイム セラピューティクス, インコーポレイテッド Staphylococcusaureusに対してワクチン接種するための方法および組成物
WO2014144211A2 (en) * 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"VULVOVAGINAL CANDIDIASIS -2015 SEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES", CDC, 2015, [RET, JPN6021004172, ISSN: 0004588865 *
THE NEW ENGLAND JOURNAL OF MEDICINE, 2004, VOL.351, NO.9, PP.876-883, JPN6021004171, ISSN: 0004588864 *
VACCINE, 2012, VOL.30, NO.52, PP.7594-7600, JPN6021004167, ISSN: 0004588863 *
VACCINE, 2013, VOL.31, PP.5549-5556, JPN6021004165, ISSN: 0004588862 *
VIRULENCE, 2015, VOL.6, NO.4, PP.309-315, JPN6021004163, ISSN: 0004588861 *

Also Published As

Publication number Publication date
US10857216B2 (en) 2020-12-08
EP3426287A4 (en) 2020-03-11
EP3426287A1 (en) 2019-01-16
WO2017155949A1 (en) 2017-09-14
CN108883167A (zh) 2018-11-23
US20190076512A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
US10857216B2 (en) Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
AU2011234656B2 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
US11020468B2 (en) Compositions, methods and therapies for administering antigen peptide
TW201536311A (zh) 基於毒素之治療性肽的眼科用途及其醫藥組合物
ES3023741T3 (en) Depot systems comprising glatiramer acetate
US20250381144A1 (en) Tabletization of peptide self-assemblies and methods of making and using the same
TWI583392B (zh) 感染的治療或預防
US20250268998A1 (en) Methods of treatment for candida auris infections
JP2019110918A (ja) 真菌病原体および細菌病原体を処置するための組成物および方法
JP2019537555A5 (cg-RX-API-DMAC7.html)
JP2019537555A (ja) ヘルペスを処置するための方法および組成物
JP2024503452A (ja) ヒトパピローマウイルスウイルス様粒子ワクチンの安定な調製
TWI225790B (en) New vaccine and method of use
TW202140069A (zh) Hpv疫苗
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
BR112020016221A2 (pt) Tratamento da doença celíaca com partículas tolerogênicas
US9926342B2 (en) Recombinant VapA and VapC peptides and uses thereof
AU2007254837A1 (en) Combination therapy method and formulation
EP3552620A1 (en) Methods of treatment for candida auris infections
KR20220038743A (ko) 항원성 폴리펩티드 및 이의 사용 방법
US20250121091A1 (en) Particles with covalently lipid-bound immunostimulatory agents
JP2013512279A (ja) IgE媒介性疾患の処置方法
WO2026024796A2 (en) Vaccine for brucellosis
HK40015673A (en) Methods of treatment for candida auris infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210907